Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Stocks
Currencies
Cryptocurrencies
Metals
Indices
Commodities
ETFs
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
News
Top Providers News
Top Providers News
Symbols
Market
Provider
Time
Symbols
News
Provider
2026.11.02
Realty Income Raises FY2026 FFO Guidance from $4.44-$4.45 to $4.45-$4.46 vs $4.37 Est
Benzinga
2026.11.02
Tactile Systems Tech Q3 EPS $0.31 Misses $0.35 Estimate, Sales $91.858M Miss $91.993M Estimate
Benzinga
2026.11.02
People Incorporated - Common Stock Q3 EPS $(9.15) Misses $(0.19) Estimate, Sales $430.820M Miss $442.412M Estimate
Benzinga
2026.11.02
CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate
Benzinga
2026.11.02
Adeia Lowers FY2026 GAAP Sales Guidance from $395.000M-$435.000M to $375.000M-$415.000M
Benzinga
2026.11.02
Hinge Health Raises FY2026 Sales Guidance from $856.000M-$860.000M to $879.000M-$881.000M vs $861.558M Est
Benzinga
2026.11.02
SI-BONE Q3 EPS $(0.08) Beats $(0.13) Estimate, Sales $55.704M Beat $55.404M Estimate
Benzinga
2026.11.02
Sabra Health Care REIT Raises FY2026 FFO Guidance from $1.53-$1.55 to $1.54-$1.55 vs $1.55 Est
Benzinga
2026.11.02
Clorox Q1 Adj. EPS $1.55 Beats $1.07 Estimate, Sales $1.905B Beat $1.876B Estimate
Benzinga
2026.11.02
Biomarin Pharmaceutical Q3 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.025B Miss $1.026B Estimate
Benzinga
2026.11.02
Hinge Health Sees Q4 Sales $249.000M-$251.000M vs $239.026M Est
Benzinga
2026.11.02
Backblaze Sees Q4 Sales $49.800M-$50.200M vs $46.988M Est
Benzinga
2026.11.02
Backblaze Raises FY2026 Sales Guidance from $172.000M-$174.000M to $177.800M-$178.200M vs $172.963M Est
Benzinga
2026.11.02
AH Realty Trust Q3 Adj. FFO $0.16 Beats $0.14 Estimate, Sales $52.323M Miss $52.577M Estimate
Benzinga
2026.11.02
Ichor Holdings Sees Q4 GAAP EPS $0.50-$0.60 vs $0.44 Est
Benzinga
2026.11.02
Onsemi Agrees To Acquire Ferric For $600M In Cash; Raises 2030 AI Data Center Revenue Target To Over $3B
Benzinga
2026.11.02
Janus Living Raises FY2026 FFO Guidance from $0.95-$0.98 to $0.97-$0.99 vs $0.97 Est
Benzinga
2026.11.02
Ichor Holdings Sees Q4 Adj EPS $0.65-$0.75 vs $0.62 Est; Sees Sales $345.000M-$365.000M vs $363.067M Est
Benzinga
2026.11.02
Waystar Holding Raises FY2026 Adj EPS Guidance from $1.61-$1.70 to $1.63-$1.71 vs $1.67 Est; Narrows FY2026 Sales Guidance from $1.276B-$1.294B to $1.277B-$1.287B vs $1.286B Est
Benzinga
2026.11.02
Barclays Maintains Overweight on TPG, Raises Price Target to $62
Benzinga
2026.11.02
Bioventus Q3 Adj. EPS $0.17 Beats $0.16 Estimate, Sales $142.442M Miss $149.461M Estimate
Benzinga
2026.11.02
V2X Raises FY2026 Adj EPS Guidance from $5.90-$6.30 to $6.15-$6.55 vs $5.94 Est; Raises FY2026 Sales Guidance from $4.875B-$5.025B to $4.950B-$5.100B vs $4.976B Est
Benzinga
2026.11.02
Vitesse Energy Q3 EPS $(0.86) vs $0.010 estimate
Benzinga
2026.11.02
Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.600B-$4.750B to $4.775B-$4.850B vs $4.719B Est
Benzinga
2026.11.02
Emergent BioSolutions Q3 Adj. EPS $(0.36) Beats $(0.39) Estimate, Sales $110.000M Miss $123.200M Estimate
Benzinga
2026.11.02
Independence Realty Trust Q3 FFO $0.29, Inline, Sales $171.967M Beat $171.203M Estimate
Benzinga
2026.11.02
Jazz Pharmaceuticals Q3 Adj. EPS $(3.88) Misses $(3.86) Estimate, Sales $1.243B Beat $1.208B Estimate
Benzinga
2026.11.02
Healthpeak Properties Raises FY2026 FFO Guidance from $1.73-$1.77 to $1.76-$1.78 vs $1.76 Est
Benzinga
2026.11.02
Barclays Maintains Equal-Weight on TIM, Lowers Price Target to $22
Benzinga
2026.11.02
Cerus Affirms FY2026 Sales Guidance of $229.000M-$231.000M vs $248.850M Est
Benzinga
1
...
320
321
322
323
324
325
...
712
>